Silence Therapeutics plc
SLN$206M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON116 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 1, 2026
6wMarket Overview
Stock performance and key metrics
SLN News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
SLN124
Polycythemia Vera
SLN360
Cardiovascular Diseases
Atu027 & gemcitabine in lead in safety period
Carcinoma, Pancreatic Ductal
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SLN124 | Phase 2 | Polycythemia Vera | - | - |
SLN360 | Phase 2 | Cardiovascular Diseases | - | - |
Atu027 & gemcitabine in lead in safety period | Phase 2 | Carcinoma, Pancreatic Ductal | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply